SELLAS Life Sciences (SLS) Shares Outstanding (Weighted Average) (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $172.5 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 96.54% year-over-year to $172.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.5 million (up 96.54% YoY) and the FY2025 annual result came in at $109.1 million, up 588.06% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $172.5 million in Q1 2026 per SLS's latest filing, from $22.4 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $172.5 million in Q1 2026 and bottomed at $518000.0 in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $27.8 million (2023), against an average of $45.6 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) sank 96.52%; it then soared 2286.29% in 2023.
• Tracing SLS's Shares Outstanding (Weighted Average) over 5 years: stood at $5.1 million in 2022, then surged by 440.31% to $27.8 million in 2023, then plunged by 42.94% to $15.8 million in 2024, then surged by 41.11% to $22.4 million in 2025, then surged by 671.25% to $172.5 million in 2026.
• Per Business Quant, the three latest SLS Shares Outstanding (Weighted Average) figures stand at $172.5 million (Q1 2026), $22.4 million (Q4 2025), and $98.3 million (Q3 2025).

Peer Comparison